# Neuralink — Healthcare Investment Intelligence

> medical_device · Series E. MedFuel Intel profile as of 2026-06-12.

Neuralink is developing implantable brain-computer interfaces, including the N1 implant, to let people with paralysis control devices with their thoughts and to eventually restore motor, sensory, and visual functions. It was founded in 2016 and has reported human clinical trials and first human implant work in 2024-2025.

## Key facts (as of 2026-06-12)
- Sector: medical_device
- Stage: Series E
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-34. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.